Enterprise Value
776M
Cash
739.2M
Avg Qtr Burn
-76.73M
Short % of Float
10.54%
Insider Ownership
1.35%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia | Approved Quarterly sales | |
Tibsovo (Ivosidenib) (IDH1m inhibitor) Details AML (Acute Myeloid Leukemia) | Approved Quarterly sales | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Pyruvate Kinase Deficiency | Phase 3 Data readout | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Beta thalessemia | Phase 3 Data readout | |
Vorasidenib (Pan-IDHm inhibitor) Details Glioma, Brain tumor | Phase 3 Update | |
PYRUKYND (Mitapivat) (pyruvate kinase R (PKR) activator) Details Sickle cell disease, Anemia | Phase 2 Data readout | |
AG-946 Details Myelodysplastic syndrome | Phase 2a Data readout |